Chronic stress and glucocorticoid receptor resistance in asthma

• Autores: Palumbo, María Laura; Prochnik, Andrés; Wald, Miriam Ruth; Genaro, Ana María
• Año de publicación: 2020
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Clinical Therapeutics. 2020
• Materia: ASMA; CORTICOIDES; TRATAMIENTO MEDICO; TRATAMIENTO FARMACOLOGICO; ESTRES; FACTORES PSICOLOGICOS
• Institución: Pontificia Universidad Católica Argentina

Fil: Palumbo, María Laura. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires; Argentina
Fil: Palumbo, María Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Prochnik, Andrés. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomedicas; Argentina
Fil: Prochnik, Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Wald, Miriam Ruth. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomedicas; Argentina
Fil: Wald, Miriam Rut. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Genaro, Ana María. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Farmacología; Argentina
Abstract: Purpose: Chronic and persistent exposure to negative stress can lead to adverse consequences on health. Particularly, psychosocial factors were found to increase the risk and outcome of respiratory diseases like asthma. Glucocorticoids (GCs) are the most efficient anti-inflammatory therapy for asthma. However, a significant proportion of patients don’t respond adequately to GC administration. GC sensitivity is modulated by genetic and acquired disease-related factors. Additionally, it was proposed that endogenous corticosteroids may limit certain actions of synthetic GCs, contributing to insensitivity. Psychological and physiological stresses activate the hypothalamic-pituitary-adrenal axis, increasing cortisol levels. Here, we review the mechanism involved in altered GC sensitivity in asthmatic patients under stressful situations. Strategies for modulation GC sensitivity and improving GC therapy are discussed. Methods: PubMed was searched for publications on psychological chronic stress and asthma, GC resistance in asthma, biological mechanisms for GC resistance, and drugs for steroid-resistant asthma, including highly potent GCs. Findings: GC resistance in patients with severe disease remains a major clinical problem. In asthma, experimental and clinical evidence suggests that chronic stress induces inflammatory changes, contributing to a worse GC response. GC resistant patients can be treated with other broad-spectrum anti-inflammatory drugs, but these generally have major side effects. Different mechanisms of GC resistance have been described and might be useful for developing new therapeutic strategies against it. Novel drugs, such as highly potent GCs, phosphoinositide 3-kinase-delta inhibitors that reestablish histone deacetylase-2 function, decrease of GC receptor phosphorylation by p38 mitogenactivated protein kinase inhibitors, or phosphatase activators, are currently in clinical development and might be combined with GC therapy in the future. Furthermore, microRNAs (small noncoding RNA molecules) operate as posttranscriptional regulators, providing another level of control of GC receptor levels. Empirical results allow postulating that the detection and study of microRNAs might be a promising approach to better characterize and treat asthmatic patients. Implications: Many molecular and cellular pathobiological mechanisms are responsible of GC resistance. Therefore detecting specific biomarkers to help identify patients who would benefit from new therapies is crucial. Stress consitutes a negative aspect of current lifestyles that increase asthma morbidity and mortality. Adequate stress management could be an important and positive intervention. Key words: asthma, chronic stress, glucocorticoid resistance, pharmacologic strategies.